Fayuvi Approved for Sanfilippo Syndrome Type A
On Sept. 17, 2026, the US Food and Drug Administration (FDA) approved Ultragenyx Pharmaceutical’s Fayuvi™ (rebisufligene etisparvovec-hopf) for the treatment of neurologic manifestations in pediatric patients who have mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. Fayuvi is a one-time, adeno-associated virus serotype 9 (AAV9) gene therapy that delivers a functional copy of the N-sulfoglucosamine sulfohydrolase (SGSH) gene, enabling cells to produce the missing sulfamidase enzyme and clear toxic heparan sulfate from the brain and body. The recommended dose is 3.0 x 1013 vector genomes (vg) per kg of body weight, given as a single intravenous (IV) infusion. Corticosteroids begin one day before infusion and continue for at least eight weeks. Ultragenyx expects to ship the commercial product to qualified treatment centers within 30 to 60 days; the company has not disclosed a price. Here is the prescribing information.
At a Glance
- Brand Drug: Fayuvi™ (rebisufligene etisparvovec-hopf)
- Manufacturer: Ultragenyx Pharmaceutical Inc. (Ultragenyx)
- Date Approved: Sept. 17, 2026
- Indication: Treatment of neurologic manifestations of MPS IIIA (Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function.
- Dosage Forms Available: Single-dose vials of 2mL extractable volume for IV infusion, supplied in a kit sized to the patient’s body weight. Each kit contains five to 105 single-dose vials, depending on the patient’s weight.
- Launch Date: Commercial product to ship to qualified treatment centers within 30 to 60 days of approval
- Estimated Annual Cost: Not yet known
- FDA Designation: Orphan Drug Designation, Fast Track, Breakthrough Therapy, Priority Review.
- MPS IIIA, or Sanfilippo syndrome type A, is an inherited, ultra-rare lysosomal storage disorder marked by progressive neurodegeneration. Variants in the SGSH gene cause a deficiency of sulfamidase, also called heparan N-sulfatase, one of four enzymes that break down the glycosaminoglycan (GAG) heparan sulfate. Heparan sulfate then accumulates and progressively damages the central nervous system. MPS IIIA typically presents between 1 year and 4 years of age and progresses rapidly.
- Children first show delayed cognition, delayed speech and behavioral problems that progress to hyperactivity, abnormal movements, aggression, difficulty with toilet training, vision loss, hearing difficulty, loss of motor function and sleep disorders. In later stages, patients lose the ability to walk, develop difficulty swallowing and seizures and become bedridden, with increased risk for infection and nutritional deficiency that often requires a feeding tube.
- MPS III is the most common mucopolysaccharidosis, with an estimated incidence of about one in 70,000 newborns across all four subtypes, and type A is the most common subtype. Ultragenyx estimates that 3,000 to 5,000 patients across commercially accessible geographies live with Sanfilippo syndrome type A.
- Approval is based on Transpher A, an open-label, single-arm, multicenter study of pediatric patients with MPS IIIA between 2 years and 5 years of age. Researchers compared changes in cognitive scores with an untreated historical control group. Children who received Fayuvi maintained or improved their cognitive, language and motor skills during the years when untreated children are expected to plateau and then decline, a difference the FDA described as clinically meaningful. Treated patients scored 23.5 points higher on the Bayley-III cognitive raw score than the untreated cohort. Cerebrospinal fluid heparan sulfate, the toxic sugar that builds up in the brain, declined and remained reduced across all age groups. Follow-up extended to 8.5 years, with a median of 4.8 years.
- Adverse reactions reported in 5% or more of patients included elevated liver enzymes, vomiting, fever, decreased white blood cell count, decreased appetite, decreased platelet count, nausea and elevated amylase levels.
- No other FDA-approved disease-modifying therapy exists for Sanfilippo syndrome type A. Care has been limited to symptom management, including antiseizure medications, behavioral and sleep interventions, therapy services, nutritional support and palliative care.
- Pipeline therapies in development for MPS IIIA include Kyowa Kirin’s OTL-201, a one-time autologous hematopoietic stem cell gene-modified therapy that uses a lentiviral vector to insert a functional SGSH gene into the patient’s own blood stem cells and is currently in phase II development. Also in phase II development, Denali Therapeutics’ DNL126 is an IV enzyme replacement therapy that uses the company’s Enzyme Transport Vehicle to cross the blood-brain barrier via the transferrin receptor. Unlike gene therapies, DNL126 requires repeat infusions. Denali anticipates filing for accelerated approval in 2027.